ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,132,327 | -39.1% | 56,447 | -14.4% | 0.00% | -33.3% |
| Q2 2023 | $1,860,196 | +87.9% | 65,941 | +14.6% | 0.00% | +200.0% |
| Q1 2023 | $990,084 | -15.7% | 57,563 | -1.3% | 0.00% | -50.0% |
| Q4 2022 | $1,175,109 | -6.1% | 58,347 | +1.0% | 0.00% | 0.0% |
| Q3 2022 | $1,251,000 | -19.4% | 57,749 | +4.5% | 0.00% | 0.0% |
| Q2 2022 | $1,553,000 | -3.5% | 55,270 | +58.4% | 0.00% | 0.0% |
| Q1 2022 | $1,609,000 | -50.8% | 34,882 | -10.4% | 0.00% | -50.0% |
| Q4 2021 | $3,273,000 | +35.4% | 38,935 | +7.3% | 0.00% | +33.3% |
| Q3 2021 | $2,418,000 | -0.9% | 36,286 | -20.8% | 0.00% | 0.0% |
| Q2 2021 | $2,439,000 | +29.7% | 45,837 | +5.7% | 0.00% | +50.0% |
| Q1 2021 | $1,881,000 | -16.7% | 43,349 | -0.3% | 0.00% | -33.3% |
| Q4 2020 | $2,258,000 | +296.1% | 43,480 | +149.3% | 0.00% | +200.0% |
| Q3 2020 | $570,000 | -23.8% | 17,444 | +11.9% | 0.00% | 0.0% |
| Q2 2020 | $748,000 | – | 15,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |